Esther Taks
A5030189168- Immune responses and vaccinations
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Impact on Reproduction
- COVID-19 epidemiological studies
- Influenza Virus Research Studies
- Gut microbiota and health
- Immunotherapy and Immune Responses
- Sepsis Diagnosis and Treatment
- Antibiotic Use and Resistance
- Thermal Regulation in Medicine
- COVID-19 and Mental Health
- T-cell and B-cell Immunology
- Nosocomial Infections in ICU
- Immunodeficiency and Autoimmune Disorders
- SARS-CoV-2 detection and testing
- Complement system in diseases
- Immune Cell Function and Interaction
- Viral Infections and Outbreaks Research
Radboud University Nijmegen
2020-2024
Radboud University Medical Center
2020-2024
University Medical Center
2024
Non-specific protective effects of certain vaccines have been reported, and long-term boosting innate immunity, termed trained has proposed as one the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received previous vaccination: relative risk reductions 37% 49% were observed following during...
In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG) vaccination reduced occurrence new infections compared to placebo in elderly. Most benefit was found for respiratory infections. The ACTIVATE-2 launched assess efficacy BCG against coronavirus disease 2019 (COVID-19). this multicenter, double-blind trial, 301 volunteers aged 50 years or older were randomized (1:1) be vaccinated placebo. trial end points incidence COVID-19 and presence anti–severe acute...
Abstract Background Older age is associated with increased severity and death from respiratory infections, including coronavirus disease 2019 (COVID-19). The tuberculosis BCG vaccine may provide heterologous protection against nontuberculous infections has been proposed as a potential preventive strategy COVID-19. Methods In this multicenter, placebo-controlled trial, we randomly assigned older adults (aged ≥60 years; n = 2014) to intracutaneous vaccination (n 1008) or placebo 1006). primary...
Excessive activation of immune responses in coronavirus disease 2019 (COVID-19) is considered to be related severity, complications, and mortality rate. The complement system an important component innate immunity can stimulate inflammation, but its role COVID-19 unknown.A prospective, longitudinal, single center study was performed hospitalized patients with COVID-19. Plasma concentrations factors C3a, C3c, terminal complex (TCC) were assessed at baseline during hospital admission. In...
Bacille Calmette-Guérin (BCG) induces long-term boosting of innate immunity, termed trained and decreases susceptibility to respiratory tract infections. BCG vaccination trials for reducing SARS-CoV-2 infection are underway, but concerns have been raised regarding the potential harm strong immune responses. To investigate safety vaccination, we retrospectively assessed coronavirus disease 2019 (COVID-19) related symptoms in three cohorts healthy volunteers who either received last 5 years or...
Objectives: The COVID-19 pandemic increases healthcare worker (HCW) absenteeism.The bacillus Calmette-Gu erin (BCG) vaccine may provide non-specific protection against respiratory infections through enhancement of trained immunity.We investigated the impact BCG vaccination on HCW absenteeism during pandemic.Methods: HCWs exposed to patients in nine Dutch hospitals were randomized or placebo a 1:1 ratio, and followed for one year using mobile phone application.The primary endpoint was...
Novel mRNA-based vaccines have been used to protect against SARS-CoV-2, especially in vulnerable populations who also receive an annual influenza vaccination. The TACTIC study investigated potential immune interference between the mRNA COVID-19 booster vaccine and quadrivalent vaccine, determined if concurrent administration would effects on safety or immunogenicity.TACTIC was a single-blind, placebo-controlled randomized clinical trial conducted at Radboud University Medical Centre,...
While several BCG trials in adults were conducted during the 2019 coronavirus disease epidemic, our data set is most comprehensive to date, because we included serologically confirmed infections addition self-reported positive SARS-CoV-2 test results. We also collected on symptoms for every day 1-year follow-up period, which enabled us characterize detail.
ABSTRACT Every year, influenza causes 290.000 to 650.000 deaths worldwide and vaccination is encouraged prevent infection in high-risk individuals. Interestingly, cross-protective effects of against heterologous infections have been reported, long-term boosting innate immunity (also termed trained ) has proposed as the underlying mechanism. Several epidemiological studies also suggested cross-protection between COVID-19 during current pandemic. However, mechanism behind such an effect...
SUMMARY BCG vaccination induces heterologous protection against respiratory tract infections, and in children improves survival independently of tuberculosis prevention. The phase III ACTIVATE-2 study assessed whether could also protect COVID19 the elderly. In this double-blind, randomized trial, elderly Greek patients were (1:1) to receive either revaccination or placebo at hospital discharge, followed by 6 months observation for incidence infection. resulted 68% risk reduction total...
ABSTRACT Non-specific protective effects of certain vaccines have been reported, and long-term boosting innate immunity, termed trained immunity , has proposed as one the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received previous vaccination: relative risk reductions 37% 49% were observed...
Abstract While several effective therapies for critically ill patients with COVID-19 have been identified in large, well-conducted trials, the mechanisms underlying these not investigated depth. Our aim is to investigate association between various immunosuppressive (corticosteroids, tocilizumab and anakinra) change endothelial host response over time patients. We conducted a pre-specified multicenter post-hoc analysis Dutch cohort of admitted ICU March 2020 September 2021 due hypoxemic...
SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines S-protein only. The BCG-Corona trial, initiated in March 2020 SARS-CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks introduction of during one-year follow-up. We assessed determinants systemic anti-S1 anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomised to BCG or placebo vaccination, reported daily symptoms, test...
Protective heterologous beneficial effects of vaccines have been reported, and in this study we aimed to assess the impact routine pneumococcal influenza vaccination on incidence symptom duration COVID-19 a population Dutch older adults. This cohort is secondary analysis BCG-CORONA-ELDERLY study, randomised controlled trial effect BCG cumulative respiratory tract infections requiring medical intervention adults ≥ 60 years. The primary outcome was self-reported positive SARS-CoV-2 PCR test,...
Background and objective A recent study has suggested that circadian rhythm an important impact on the immunological effects induced by Bacillus Calmette-Guérin (BCG) vaccination. The of this was to evaluate whether timing BCG vaccination (morning or afternoon) affects its severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infections clinically relevant tract (RTIs). Methods This is a post-hoc analysis BCG-CORONA-ELDERLY (NCT04417335) multicenter, placebo-controlled trial, in which...
Summary SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines S-protein only. The BCG-Corona trial, initiated in March 2020 SARS-CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks introduction of during one-year follow-up. We assessed determinants systemic anti-S1 anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomized to BCG or placebo vaccination, reported daily symptoms,...